Paul Yazaki, Ph.D.

626-256-4673
Yazaki Paul
Research Professor, Department of Immunology & Theranostics
Research Area
Antibody Engineering Novel Molecules for Clinical Applications

Location

Education & Experience

Degrees

  • 1992, Ph.D., Cell and Molecular Biology, University of California San Diego and San Diego State University Joint Doctoral Program, San Diego, CA

  • 1974, B.S., Biology, University of California San Diego, La Jolla, CA

Professional Experience

  • 2018-present, Research Professor, Department of Immunology & Theranostics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA

  • 2016-present, Director of Clinical Production, Center for Theranostic Studies, Beckman Research Institute City of Hope, Duarte, CA

  • 2012-2018, Research Professor, Department of Molecular Immunology, Beckman Research Institute City of Hope, Duarte, CA.

  • 2009-2012, Research Professor, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA

  • 2003-2009, Associate Research Scientist, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA

  • 2001-2003, Associate Research Scientist, Division of Molecular Biology, Beckman Research Institute of City of Hope, Duarte, CA

  • 1996-2001, Assistant Research Scientist, Division of Molecular Biology, Beckman Research Institute of City of Hope, Duarte, CA

  • 1993-1996, Postdoctoral Fellow, Hybritech Inc., Department of Protein Engineering, La Jolla, CA

  • 1985-1992, Joint-Doctoral Research Associate, Molecular Biology Institute, San Diego State University, San Diego, CA

  • 1974-1985, Staff Research Associate IV, Department of Medicine, University of California San Diego, La Jolla, CA

Research

Lab Members

The research focus of Paul Yazaki, Ph.D., is antibody engineering novel molecules for clinical applications. The scope of this research includes recombinant antibodies, antibody fragments, fusion proteins and antibody-based nanoparticles for the imaging and therapy of cancer. Areas of expertise include antibody design, discovery, engineering, expression, purification, biophysical characterization, in vivo preclinical animal models, process development and cGMP production.

Publications

  • Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, Clayton KL, Raab M, Chen Q, Beauchemin N, Yazaki PJ, Pyzik M, Ostrowski MA, Glickman JN, Rudd CE, Ploegh HL, Franke A, Petsko GA, Kuchroo VK, Blumberg RS. (2015) CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, Jan 15;517(7534):386-90.